SIGN updates its guideline on the management of migraine
Abstract
The Scottish Intercollegiate Guidelines Network (SIGN) has recently updated its guideline on the pharmacological management of migraine (SIGN 155) to include new information on the use of anti‐CGRP monoclonal antibodies. This article provides a round‐up of the main changes to the guidance.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.